Please use this identifier to cite or link to this item:
|Title:||Safety and efficacy of radioallergosorbent test-based allergen immunotherapy in treatment of perennial allergic rhinitis and asthma||Authors:||Yeoh, K.H.
|Issue Date:||2004||Citation:||Yeoh, K.H., Wang, D.Y., Gordon, B.R. (2004). Safety and efficacy of radioallergosorbent test-based allergen immunotherapy in treatment of perennial allergic rhinitis and asthma. Otolaryngology - Head and Neck Surgery 131 (5) : 673-678. ScholarBank@NUS Repository. https://doi.org/10.1016/j.otohns.2004.04.020||Abstract:||This study was undertaken to demonstrate the safety and efficacy of in vitro, radioallergosorbent test (RAST)-based inhalant allergen immunotherapy. Prospective 22 year single site clinical study, with outcome evaluations of 480 perennial allergic rhinitis patients, including 96 with concomitant asthma. Rhinitis symptom control after 2 years of immunotherapy was excellent in 32.5% of patients, good in 45.6%, and fair in 14.2%. There was no improvement in 7.7%. For patients with asthma, 81% had good or excellent pulmonary symptom improvement, and no patient failed to improve. No severe reactions occurred, but there were 5 limited systemic reactions, or 0.008% of injections, during a 2.5-year mean immunotherapy treatment course. RAST-based immunotherapy is safe and effective for patients with perennial allergic rhinitis, with or without concomitant asthma. This is the first large, multiyear study of safety and efficacy of RAST-based immunotherapy for treatment of perennial allergic rhinitis and asthma. EBM rating: C.||Source Title:||Otolaryngology - Head and Neck Surgery||URI:||http://scholarbank.nus.edu.sg/handle/10635/33982||ISSN:||01945998||DOI:||10.1016/j.otohns.2004.04.020|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.